A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2011 |
| End Date: | September 2015 |
A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in
patients with Chondrosarcoma.
Study IPI-926-04 is a Phase 2, double-blind, placebo-controlled, multicenter, trial
evaluating the safety and efficacy of IPI-926 in patients with metastatic or locally
advanced (unresectable) chondrosarcoma. The study includes an optional cross-over to
open-label IPI-926 for patients randomly assigned to placebo who experience documented
disease progression.
We found this trial at
1
site
Click here to add this to my saved trials
